# A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide

Study · id `cardio:ct-nct02222480` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02222480](<https://clinicaltrials.gov/study/NCT02222480>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02222480

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT02222480. Randomized; double masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT02222480, source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)
- Start date: 2014-10 (registry gives no type) (ClinicalTrials.gov record NCT02222480, source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)
- Primary completion: 2015-05 (actual) (ClinicalTrials.gov record NCT02222480, source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT02222480, source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02222480, source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02222480-2016-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
- Condition: Hypertension
- Intervention (Drug): Fimasartan
- Intervention (Drug): Hydrochlorothiazide
- Intervention (Drug): Placebo
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY
- Collaborator: Seoul National University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Hydrochlorothiazide (`cardio:hydrochlorothiazide`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)
- Registry lists this organization as a collaborator: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)

## Provenance

Content hash: 8b1c4cde45534784374dfe694ee9d1a48a16760c7e3d679130bd65b27e1937b7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
